Karly Borunda
Family · Orange, CANPI 1174179725
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 125 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 26 manufacturers, the largest accounting for just 20.1% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2021 at $2,159 and has fallen 89.8% since, to $221 in 2023.
Across 125 payments — averaging $19.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$500
- CSL Behring$278
- Biogen$213
- SK Life Science, Inc.$202
- Biohaven Pharmaceuticals, Inc.$200
- Eisai Inc.$121
- plus $976 from 20 others
What the payments were for
- Food & beverage$2,491100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 24 | $500 |
| CSL Behring | 11 | $278 |
| Biogen | 11 | $213 |
| SK Life Science, Inc. | 9 | $202 |
| Biohaven Pharmaceuticals, Inc. | 10 | $200 |
| Eisai Inc. | 7 | $121 |
| EMD Serono, Inc. | 7 | $101 |
| Novartis | 6 | $96 |
| AstraZeneca | 4 | $94 |
| Adamas Pharmaceuticals, Inc. | 5 | $84 |
| Lundbeck LLC | 3 | $79 |
| Amgen | 3 | $74 |
| Amneal Pharmaceuticals LLC | 4 | $70 |
| Upsher-smith Laboratories LLC | 4 | $69 |
| Lilly USA, LLC | 2 | $38 |
| Johnson & Johnson | 2 | $35 |
| Neurelis, Inc. | 2 | $34 |
| Banner Life Sciences, LLC | 2 | $34 |
| Tanabe Pharma America, Inc. | 2 | $34 |
| Genentech USA, Inc. | 1 | $23 |
| UCB, Inc. | 1 | $23 |
| Neurocrine Biosciences, Inc. | 1 | $23 |
| Sunovion Pharmaceuticals Inc. | 1 | $20 |
| Jazz Pharmaceuticals Inc. | 1 | $20 |
| Avanir Pharmaceuticals, Inc. | 1 | $14 |
| Merck | 1 | $12 |
How this compares
$2,491 in reported general payments places this provider in the 85th percentile of 10,634 family providers in California.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Memantine Hcl | 11 | $246 |
| Ondansetron Hcl | 28 | $135 |
| Donepezil Hcl | 16 | $28 |
Paid to pharmacies, not to this prescriber.
Other family in Orange
- Lori RobertsonChino Hills$475K
- Annette ShonLos Angeles$406K
- Lisa HigginsHanford$311K
- Jennifer TougasBakersfield$302K
- Kim SchaferSacramento$288K
- Dawn MeyerSan Diego$270K
- Jennifer KangCerritos$255K
- Erin DwyerSan Diego$189K
- Phyllis CasonLos Angeles$187K
- Gabriel SchwartzSan Francisco$166K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.